2011 Fiscal Year Final Research Report
Development of the molecular basis of novel therapeutic strategy for heart failure by the control of cardiac remodeling
| Project/Area Number |
22790693
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Circulatory organs internal medicine
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
TANAKA Hirotoshi 東京大学, 医科学研究所, 准教授 (00171794)
SHIMIZU Noriaki 東京大学, 医科学研究所, 特任研究員 (30396890)
SANO Motoaki 慶應義塾大学, 医学部, 講師 (30265798)
|
|---|
| Project Period (FY) |
2010 – 2011
|
| Keywords | 心肥大 / 心臓リモデリング / 心不全 / HEXIM1 / 転写伸長反応 / P-TEFb / RNAポリメラーゼII |
|---|
| Research Abstract |
[Objectives] Because HEXIM is the only molecule to inhibit P-TEFb, which is the key molecule for development of cardiac hypertrophy, we speculate that HEXIM1 may be a candidate for preventing cardiac hypertrophy/remodeling.[ Methods and Results] Using adenovirus mediated gene delivery to the cultured cardiac myocytes and a new transgenic mouse model with conditional myocardial overexpression of HEXIM1, we confirmed that overexpression of HEXIM1 in the cardiac myocytes prevents cardiac myocyte hypertrophy both in vitro and in vivo.[ Conclusion] HEXIM1 may be a candidate for preventing cardiac hypertrophy/remodeling.
|
